TENDEL THERAPIES INC

Kensington, CA · Biotech · Private

Genetic adjuvants that target T follicular helper cells to enhance immunogenicity of HIV envelope protein immunogens

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Headquarters: Kensington, CA
Total capital: $5.9M

Federal grants: $5.3M; 11 awards · 2020–2025; Rank in peer group#8 of 502
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $600K; 1 award · Health and Human S; Rank in Biotech#219 of 4373
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Aug 2025Federal grantHealth and Human S · Phase II · Optimizing SIV reservoir depletion by Tendel bsAb-98$1.0M
May 2024Federal grantHealth and Human S · Phase II · GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine$572K
Jan 2024Federal grantHealth and Human S · Phase I · Genetic adjuvants to elicit neutralizing antibodies against HIV$300K
Sep 2023Federal contractHealth and Human S · Tendel Therapies, Inc. (75N93023C00030) Title: Tfh-targeting Genetic Adjuvants To Promote Durable Anti-influenza Stem Antibodies In Older Adults.$600K
Jul 2023Federal grantHealth and Human S · Phase II · GMP production and GLP safety of bidirectionally targeted SARS-CoV-2 booster vaccine$1M
Jun 2023Federal grantHealth and Human S · Phase I · CCR5 immunotoxins as components of HIV cure regimens$300K
Feb 2023Federal grantHealth and Human S · Phase I · Genetic adjuvants to elicit neutralizing antibodies against HIV$301K

Show 5 earlier federal awards

Feb 2023Federal grantHealth and Human S · Phase I · Genetic adjuvants to elicit neutralizing antibodies against HIV$301K
Jul 2022Federal grantHealth and Human S · Phase I · CCR5 immunotoxins as components of HIV cure regimens$600K
Jul 2022Federal grantHealth and Human S · Phase I · CCR5 immunotoxins as components of HIV cure regimens$300K
Dec 2020Federal grantHealth and Human S · Phase I · Memory-promoting Ad vaccine for long-lived protection against SARS-CoV-2$300K
Apr 2020Federal grantHealth and Human S · Phase I · Nucleic acid-based formulation of cytomegalovirus-vectored HIV vaccines$300K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

Federal grants#8 · top 2%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

NEUCYTE INCSimilar federal contract value in Biotech · $602K in contracts
TEICHOS LABORATORIES, LLCSimilar federal contract value in Biotech · $600K in contracts
Proteovista LLCSimilar federal contract value in Biotech · $600K in contracts
EVIMERO, LLCSimilar federal contract value in Biotech · $597K in contracts
Protein Innovation Labs, Inc.Similar federal contract value in Biotech · $586K in contracts
MOLECULAR TARGETING TECHNOLOGIES, INC.Similar federal contract value in Biotech · $573K in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.